Figures computed from official regulatory filings — .
Analysttarget 8 USD (-53%)
Ownershipinsiders 23.79% · institutions 86.14% · short 1.3% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Rallybio Corp only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
31 buys15 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Lieber Jonathan I | Exercise | $30.4K | Unusual size | SEC |
| Lieber Jonathan I | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Liu Hui | Exercise | $64.5K | SEC |
| Liu Hui | ExerciseD (derivative) | $47.5K | SEC |
| Liu Hui | Exercise | $8.5K | SEC |
| Liu Hui | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Chung Wendy | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Chung Wendy | Exercise | $8.5K | SEC |
| Boudreau Helen M | Exercise | $8.5K | SEC |
| Boudreau Helen M | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| ADAR1 Capital Management, LLCtrack record | Buy | $2.8K | conv 17 | SEC |
| ADAR1 Capital Management, LLCtrack record | Buy | $84K | conv 17 | SEC |
| ADAR1 Capital Management, LLCtrack record | Buy | $139.8K | conv 17 | SEC |
| ADAR1 Capital Management, LLCtrack record | Buy | $1.4K | conv 17 | SEC |
| ADAR1 Capital Management, LLCtrack record | Buy | $1.1M | conv 32 | SEC |
| ADAR1 Capital Management, LLCtrack record | Buy | $2.8K | conv 17 | SEC |
| ADAR1 Capital Management, LLCtrack record | Buy | $56.3K | conv 17 | SEC |
| ADAR1 Capital Management, LLCtrack record | Buy | $350K | conv 18 | SEC |
| ADAR1 Capital Management, LLCtrack record | Buy | $71.4K | conv 17 | SEC |
| ADAR1 Capital Management, LLCtrack record | Buy | $11.1K | conv 17 | SEC |
| ADAR1 Capital Management, LLCtrack record | Buy | $278.6K | conv 18 | SEC |
| ADAR1 Capital Management, LLCtrack record | Buy | $1.6M | conv 58Unusual sizeFirst in 12mo | SEC |
| ADAR1 Capital Management, LLCtrack record | Buy | $491.3K | conv 20 | SEC |
| ADAR1 Capital Management, LLCtrack record | Buy | $54.2K | conv 40First in 12mo | SEC |
| Lieber Jonathan I | Sell | $4K | SEC |